Could we soon have a simple blood test for all cancers? A test that is able to detect every form of cancer through a DNA blood screening, long before any symptoms arise?
Before you write that idea off as a foolhardy quest similar to the hunt for the Holy Grail, you should know that llumina (NASDAQ: ILMN), the company that brought us effective, cheap sequencing of DNA, hopes to roll out exactly such a test by 2019.